 John Kinsella
Concepts (676)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 88 | 2023 | 915 | 7.530 |
Why?
| | Hernias, Diaphragmatic, Congenital | 26 | 2024 | 201 | 6.240 |
Why?
| | Persistent Fetal Circulation Syndrome | 37 | 2023 | 137 | 5.000 |
Why?
| | Respiratory Insufficiency | 29 | 2023 | 318 | 3.420 |
Why?
| | Hypertension, Pulmonary | 45 | 2023 | 1910 | 3.380 |
Why?
| | Extracorporeal Membrane Oxygenation | 30 | 2024 | 301 | 3.190 |
Why?
| | Bronchopulmonary Dysplasia | 18 | 2024 | 383 | 2.570 |
Why?
| | Administration, Inhalation | 70 | 2023 | 688 | 2.410 |
Why?
| | Infant, Newborn | 106 | 2024 | 6079 | 2.170 |
Why?
| | Infant, Premature | 31 | 2024 | 574 | 1.840 |
Why?
| | High-Frequency Ventilation | 20 | 2006 | 45 | 1.770 |
Why?
| | Hemodynamics | 40 | 2022 | 1113 | 1.760 |
Why?
| | Bronchodilator Agents | 12 | 2020 | 252 | 1.730 |
Why?
| | Respiratory Distress Syndrome, Newborn | 13 | 2011 | 106 | 1.640 |
Why?
| | Vasodilator Agents | 15 | 2022 | 331 | 1.630 |
Why?
| | Oxygen Inhalation Therapy | 10 | 2015 | 157 | 1.570 |
Why?
| | Pulmonary Circulation | 31 | 2006 | 429 | 1.390 |
Why?
| | Hernia, Diaphragmatic | 9 | 2021 | 65 | 1.370 |
Why?
| | Infant, Premature, Diseases | 6 | 2019 | 101 | 1.260 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2022 | 382 | 1.220 |
Why?
| | Respiration, Artificial | 25 | 2019 | 645 | 1.070 |
Why?
| | Intensive Care Units | 7 | 2018 | 827 | 1.070 |
Why?
| | Hypoxia | 19 | 2021 | 1112 | 1.020 |
Why?
| | Oxygen | 21 | 2021 | 931 | 0.960 |
Why?
| | Vascular Resistance | 29 | 2021 | 375 | 0.920 |
Why?
| | Echocardiography | 13 | 2023 | 642 | 0.870 |
Why?
| | Humans | 170 | 2024 | 137585 | 0.840 |
Why?
| | Blood Gas Analysis | 7 | 2021 | 74 | 0.830 |
Why?
| | Gestational Age | 22 | 2024 | 910 | 0.810 |
Why?
| | Lung | 33 | 2023 | 4060 | 0.800 |
Why?
| | Critical Care | 8 | 2017 | 601 | 0.800 |
Why?
| | Transportation of Patients | 3 | 2020 | 55 | 0.790 |
Why?
| | Propofol | 5 | 2024 | 73 | 0.740 |
Why?
| | Bronchoconstriction | 1 | 2020 | 32 | 0.680 |
Why?
| | Ventricular Dysfunction | 1 | 2019 | 15 | 0.650 |
Why?
| | Sheep | 40 | 2007 | 856 | 0.650 |
Why?
| | Pulmonary Gas Exchange | 11 | 2009 | 121 | 0.640 |
Why?
| | Pre-Eclampsia | 2 | 2024 | 190 | 0.610 |
Why?
| | Heart Atria | 1 | 2020 | 137 | 0.610 |
Why?
| | Anaphylaxis | 1 | 2020 | 105 | 0.610 |
Why?
| | Fetus | 21 | 2018 | 806 | 0.600 |
Why?
| | Cardiovascular System | 1 | 2020 | 137 | 0.600 |
Why?
| | Vasodilation | 20 | 2005 | 499 | 0.600 |
Why?
| | Ductus Arteriosus, Patent | 4 | 2015 | 52 | 0.600 |
Why?
| | Infant | 35 | 2024 | 9465 | 0.580 |
Why?
| | Hospital Mortality | 6 | 2018 | 911 | 0.550 |
Why?
| | Severity of Illness Index | 14 | 2024 | 2828 | 0.550 |
Why?
| | Trachea | 2 | 2018 | 237 | 0.550 |
Why?
| | Critical Illness | 5 | 2017 | 811 | 0.550 |
Why?
| | Heart Ventricles | 3 | 2020 | 788 | 0.540 |
Why?
| | Early Medical Intervention | 2 | 2014 | 57 | 0.530 |
Why?
| | Anesthetics, Intravenous | 4 | 2024 | 47 | 0.520 |
Why?
| | Pain, Postoperative | 3 | 2024 | 265 | 0.520 |
Why?
| | Pulmonary Surfactants | 6 | 2021 | 106 | 0.520 |
Why?
| | Animals, Newborn | 18 | 2007 | 844 | 0.510 |
Why?
| | Monitoring, Physiologic | 3 | 2019 | 275 | 0.500 |
Why?
| | Liver Cirrhosis | 2 | 2015 | 316 | 0.500 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 16 | 0.500 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 201 | 0.490 |
Why?
| | Hyaline Membrane Disease | 6 | 1998 | 20 | 0.490 |
Why?
| | Female | 81 | 2024 | 73304 | 0.490 |
Why?
| | Nerve Block | 1 | 2016 | 73 | 0.480 |
Why?
| | Blood Coagulation | 1 | 2017 | 255 | 0.480 |
Why?
| | Pulmonary Artery | 20 | 2021 | 1086 | 0.480 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 141 | 0.470 |
Why?
| | Morphine | 1 | 2016 | 158 | 0.470 |
Why?
| | Radial Artery | 1 | 2015 | 68 | 0.470 |
Why?
| | Umbilical Arteries | 1 | 2015 | 55 | 0.470 |
Why?
| | Treatment Outcome | 26 | 2024 | 10811 | 0.450 |
Why?
| | Male | 64 | 2024 | 67762 | 0.440 |
Why?
| | Vitamin A | 1 | 2013 | 58 | 0.420 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2016 | 177 | 0.420 |
Why?
| | Superoxide Dismutase | 2 | 2006 | 346 | 0.410 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1587 | 0.410 |
Why?
| | Oxygen Consumption | 3 | 2015 | 696 | 0.410 |
Why?
| | Knowledge Bases | 1 | 2013 | 27 | 0.400 |
Why?
| | Vitamins | 1 | 2013 | 185 | 0.380 |
Why?
| | Conscious Sedation | 2 | 2010 | 92 | 0.380 |
Why?
| | Retrospective Studies | 27 | 2024 | 15657 | 0.370 |
Why?
| | Phosphodiesterase Inhibitors | 5 | 2013 | 89 | 0.370 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 51 | 0.360 |
Why?
| | Alcohol-Related Disorders | 1 | 2013 | 122 | 0.360 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2005 | 446 | 0.350 |
Why?
| | Anesthesia, General | 2 | 2005 | 77 | 0.350 |
Why?
| | Lung Diseases | 6 | 2010 | 767 | 0.330 |
Why?
| | Paresis | 1 | 2010 | 30 | 0.330 |
Why?
| | Emergency Medicine | 1 | 2013 | 226 | 0.330 |
Why?
| | Sulfones | 4 | 2013 | 110 | 0.320 |
Why?
| | Adrenal Insufficiency | 1 | 2010 | 31 | 0.320 |
Why?
| | Decision Support Systems, Clinical | 1 | 2013 | 226 | 0.320 |
Why?
| | Dietary Supplements | 1 | 2013 | 561 | 0.310 |
Why?
| | Nitric Oxide Synthase | 15 | 2005 | 240 | 0.310 |
Why?
| | Survival Rate | 14 | 2022 | 1972 | 0.300 |
Why?
| | Dipyridamole | 6 | 1998 | 28 | 0.300 |
Why?
| | Herniorrhaphy | 2 | 2020 | 60 | 0.300 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2010 | 218 | 0.290 |
Why?
| | Pacemaker, Artificial | 1 | 2009 | 119 | 0.290 |
Why?
| | Analgesics, Opioid | 1 | 2016 | 1000 | 0.290 |
Why?
| | Nose | 2 | 2008 | 67 | 0.290 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2011 | 257 | 0.280 |
Why?
| | Meconium Aspiration Syndrome | 3 | 2003 | 11 | 0.280 |
Why?
| | Heart Defects, Congenital | 7 | 2022 | 842 | 0.270 |
Why?
| | Fluorocarbons | 2 | 1999 | 117 | 0.270 |
Why?
| | Cardiac Output | 8 | 2009 | 165 | 0.270 |
Why?
| | Foreign Bodies | 1 | 2008 | 104 | 0.260 |
Why?
| | Action Potentials | 1 | 2010 | 493 | 0.260 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 137 | 0.260 |
Why?
| | Anticoagulants | 2 | 2024 | 664 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3566 | 0.260 |
Why?
| | Pregnancy | 19 | 2024 | 6763 | 0.250 |
Why?
| | Animals | 60 | 2022 | 36940 | 0.240 |
Why?
| | Thyroidectomy | 2 | 2024 | 106 | 0.240 |
Why?
| | Child | 21 | 2022 | 21935 | 0.240 |
Why?
| | Piperazines | 3 | 2013 | 350 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 1040 | 0.230 |
Why?
| | Respiration Disorders | 1 | 2005 | 77 | 0.220 |
Why?
| | Neck Pain | 1 | 2024 | 26 | 0.220 |
Why?
| | Hirudins | 1 | 2024 | 53 | 0.220 |
Why?
| | Respiration | 3 | 2019 | 199 | 0.220 |
Why?
| | Muscle Stretching Exercises | 1 | 2024 | 19 | 0.220 |
Why?
| | Antithrombins | 1 | 2024 | 60 | 0.220 |
Why?
| | Tracheostomy | 2 | 2024 | 133 | 0.220 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 86 | 0.210 |
Why?
| | Preoperative Care | 3 | 2017 | 362 | 0.210 |
Why?
| | Ventricular Function, Left | 6 | 2020 | 534 | 0.210 |
Why?
| | Heart | 3 | 2019 | 655 | 0.210 |
Why?
| | Ductus Arteriosus | 11 | 2005 | 73 | 0.210 |
Why?
| | Pulmonary Alveoli | 3 | 2021 | 405 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 2057 | 0.200 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 69 | 0.200 |
Why?
| | Heparin | 1 | 2024 | 261 | 0.200 |
Why?
| | Double-Blind Method | 4 | 2016 | 1993 | 0.200 |
Why?
| | Fatal Outcome | 4 | 2012 | 303 | 0.200 |
Why?
| | Nitrites | 1 | 2002 | 84 | 0.200 |
Why?
| | Prospective Studies | 11 | 2023 | 7604 | 0.190 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2017 | 68 | 0.190 |
Why?
| | Antioxidants | 1 | 2006 | 584 | 0.190 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 234 | 0.190 |
Why?
| | Respiratory Therapy | 3 | 2003 | 23 | 0.190 |
Why?
| | Risk Factors | 12 | 2024 | 10388 | 0.180 |
Why?
| | Incidence | 5 | 2015 | 2804 | 0.180 |
Why?
| | Prognosis | 7 | 2023 | 4030 | 0.180 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2001 | 44 | 0.180 |
Why?
| | Precision Medicine | 2 | 2023 | 429 | 0.180 |
Why?
| | Vasoconstriction | 3 | 2005 | 202 | 0.170 |
Why?
| | Emergency Treatment | 1 | 2002 | 118 | 0.170 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2020 | 17 | 0.170 |
Why?
| | Plethysmography | 1 | 2001 | 106 | 0.170 |
Why?
| | Peptide Fragments | 1 | 2024 | 706 | 0.170 |
Why?
| | Fundoplication | 1 | 2020 | 53 | 0.170 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 600 | 0.170 |
Why?
| | Papio | 6 | 1995 | 94 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 62 | 0.160 |
Why?
| | Middle Aged | 19 | 2019 | 33479 | 0.160 |
Why?
| | Postoperative Complications | 6 | 2017 | 2654 | 0.160 |
Why?
| | Carbon Monoxide | 1 | 2000 | 81 | 0.160 |
Why?
| | Fluid Therapy | 2 | 2011 | 147 | 0.160 |
Why?
| | Time Factors | 12 | 2017 | 6828 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2019 | 1477 | 0.160 |
Why?
| | Blood Pressure | 13 | 2014 | 1786 | 0.160 |
Why?
| | Patient Care Team | 2 | 2016 | 631 | 0.160 |
Why?
| | Logistic Models | 6 | 2024 | 2074 | 0.160 |
Why?
| | Pulmonary Veins | 2 | 1999 | 99 | 0.150 |
Why?
| | Thrombelastography | 1 | 2020 | 154 | 0.150 |
Why?
| | Infusions, Intravenous | 4 | 2024 | 413 | 0.150 |
Why?
| | Aged | 15 | 2019 | 23961 | 0.150 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1389 | 0.150 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2031 | 0.150 |
Why?
| | Combined Modality Therapy | 7 | 2017 | 1236 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 173 | 0.140 |
Why?
| | United Kingdom | 3 | 2017 | 318 | 0.140 |
Why?
| | Treatment Failure | 5 | 2007 | 356 | 0.140 |
Why?
| | Risk | 3 | 2021 | 912 | 0.140 |
Why?
| | Return to Work | 1 | 2017 | 21 | 0.140 |
Why?
| | Single-Blind Method | 2 | 2013 | 282 | 0.140 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 83 | 0.140 |
Why?
| | Cerebral Hemorrhage | 2 | 2014 | 108 | 0.140 |
Why?
| | Heart Rate | 4 | 2009 | 822 | 0.140 |
Why?
| | Retinopathy of Prematurity | 1 | 2019 | 142 | 0.140 |
Why?
| | Intubation, Intratracheal | 2 | 2018 | 257 | 0.140 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 189 | 0.140 |
Why?
| | Pneumonectomy | 1 | 2019 | 152 | 0.130 |
Why?
| | Thiopental | 1 | 1997 | 4 | 0.130 |
Why?
| | Ondansetron | 1 | 1997 | 16 | 0.130 |
Why?
| | Biological Products | 1 | 2000 | 216 | 0.130 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 7 | 0.130 |
Why?
| | Adult | 18 | 2024 | 37929 | 0.130 |
Why?
| | Methemoglobin | 2 | 1993 | 21 | 0.130 |
Why?
| | Troponin I | 1 | 2017 | 81 | 0.130 |
Why?
| | Blood Circulation | 3 | 1998 | 41 | 0.130 |
Why?
| | Pulmonary Edema | 1 | 1997 | 108 | 0.130 |
Why?
| | Smoke Inhalation Injury | 3 | 1991 | 28 | 0.130 |
Why?
| | Follow-Up Studies | 10 | 2019 | 5131 | 0.130 |
Why?
| | Anesthesia, Local | 1 | 2016 | 19 | 0.130 |
Why?
| | Dyspnea | 1 | 2018 | 254 | 0.130 |
Why?
| | Capillary Permeability | 1 | 1997 | 145 | 0.130 |
Why?
| | Glycocalyx | 1 | 2016 | 27 | 0.130 |
Why?
| | Antiemetics | 1 | 1997 | 43 | 0.130 |
Why?
| | Injections, Spinal | 1 | 2016 | 105 | 0.130 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 2069 | 0.130 |
Why?
| | Cardiac Catheterization | 6 | 2022 | 530 | 0.130 |
Why?
| | Guidelines as Topic | 1 | 2018 | 275 | 0.130 |
Why?
| | Infant, Newborn, Diseases | 2 | 2014 | 113 | 0.130 |
Why?
| | Estradiol | 4 | 2001 | 521 | 0.130 |
Why?
| | Echocardiography, Doppler | 2 | 2001 | 108 | 0.130 |
Why?
| | Mentors | 1 | 2018 | 202 | 0.120 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 15 | 0.120 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1509 | 0.120 |
Why?
| | Colorectal Neoplasms | 2 | 2016 | 806 | 0.120 |
Why?
| | Child, Preschool | 14 | 2017 | 11074 | 0.120 |
Why?
| | Survivors | 1 | 2019 | 493 | 0.120 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 13 | 0.120 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2019 | 238 | 0.120 |
Why?
| | Disease Management | 2 | 2017 | 628 | 0.120 |
Why?
| | Employment | 1 | 2017 | 178 | 0.120 |
Why?
| | Down Syndrome | 1 | 2022 | 496 | 0.120 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 34 | 0.120 |
Why?
| | Nitroarginine | 10 | 2005 | 56 | 0.120 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 259 | 0.120 |
Why?
| | Length of Stay | 5 | 2017 | 1215 | 0.120 |
Why?
| | Chronic Disease | 8 | 2013 | 1793 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 740 | 0.120 |
Why?
| | Neutrophils | 3 | 1999 | 1238 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2018 | 512 | 0.120 |
Why?
| | Radiography | 2 | 2008 | 822 | 0.120 |
Why?
| | Hypnotics and Sedatives | 2 | 2024 | 200 | 0.120 |
Why?
| | Faculty, Medical | 1 | 2018 | 283 | 0.120 |
Why?
| | Cerebrovascular Circulation | 3 | 1995 | 243 | 0.120 |
Why?
| | Risk Assessment | 4 | 2017 | 3457 | 0.110 |
Why?
| | Sildenafil Citrate | 4 | 2021 | 58 | 0.110 |
Why?
| | Postoperative Care | 1 | 2016 | 261 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2015 | 307 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 322 | 0.110 |
Why?
| | Ventilator Weaning | 2 | 2005 | 36 | 0.110 |
Why?
| | Mothers | 1 | 2020 | 754 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2011 | 545 | 0.110 |
Why?
| | Ammonia | 2 | 1992 | 62 | 0.110 |
Why?
| | Vasopressins | 1 | 2014 | 64 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 284 | 0.110 |
Why?
| | Registries | 5 | 2022 | 2035 | 0.110 |
Why?
| | Biomarkers | 4 | 2016 | 4149 | 0.110 |
Why?
| | Thrombosis | 1 | 2017 | 371 | 0.100 |
Why?
| | Pediatrics | 2 | 2019 | 1101 | 0.100 |
Why?
| | Vasoconstrictor Agents | 1 | 2014 | 139 | 0.100 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2013 | 8 | 0.100 |
Why?
| | Elective Surgical Procedures | 2 | 2011 | 179 | 0.100 |
Why?
| | Survival Analysis | 3 | 2009 | 1325 | 0.100 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 1050 | 0.100 |
Why?
| | Hypotension | 1 | 2014 | 122 | 0.100 |
Why?
| | Epoprostenol | 3 | 2021 | 136 | 0.100 |
Why?
| | Hemorrhage | 1 | 2017 | 722 | 0.100 |
Why?
| | Pilot Projects | 5 | 2024 | 1710 | 0.100 |
Why?
| | Cell Nucleus | 1 | 1996 | 620 | 0.100 |
Why?
| | Cyclic GMP | 4 | 2001 | 93 | 0.100 |
Why?
| | Diaphragm | 2 | 2023 | 42 | 0.100 |
Why?
| | Renal Dialysis | 1 | 2016 | 435 | 0.100 |
Why?
| | Coronary Circulation | 2 | 1995 | 143 | 0.100 |
Why?
| | Critical Care Nursing | 1 | 2013 | 51 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2015 | 243 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2017 | 7635 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2013 | 242 | 0.090 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2011 | 9 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1353 | 0.090 |
Why?
| | Delivery Rooms | 1 | 2011 | 7 | 0.090 |
Why?
| | Cohort Studies | 5 | 2024 | 5742 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 50 | 0.090 |
Why?
| | Ventilators, Mechanical | 2 | 2016 | 58 | 0.090 |
Why?
| | Acetylcholine | 5 | 2001 | 185 | 0.090 |
Why?
| | Kidney Tubules | 1 | 1992 | 117 | 0.090 |
Why?
| | Algorithms | 3 | 2013 | 1704 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2018 | 3556 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 197 | 0.090 |
Why?
| | Respiratory Mechanics | 3 | 1999 | 67 | 0.090 |
Why?
| | Diseases in Twins | 1 | 2012 | 169 | 0.090 |
Why?
| | Cardiac Output, Low | 1 | 1991 | 66 | 0.090 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 185 | 0.090 |
Why?
| | Alfentanil | 1 | 2010 | 3 | 0.080 |
Why?
| | Monitoring, Intraoperative | 2 | 2008 | 56 | 0.080 |
Why?
| | Oocyte Retrieval | 1 | 2010 | 12 | 0.080 |
Why?
| | Delivery, Obstetric | 1 | 1991 | 144 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 7 | 2007 | 204 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 165 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 186 | 0.080 |
Why?
| | Communication | 1 | 2016 | 879 | 0.080 |
Why?
| | Thermodilution | 2 | 2005 | 13 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2007 | 1502 | 0.080 |
Why?
| | Disease Models, Animal | 7 | 2007 | 4295 | 0.080 |
Why?
| | Endothelium, Vascular | 5 | 2016 | 927 | 0.080 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2003 | 93 | 0.080 |
Why?
| | APACHE | 2 | 2017 | 69 | 0.080 |
Why?
| | Physicians | 1 | 2018 | 910 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 125 | 0.080 |
Why?
| | Positive-Pressure Respiration | 2 | 2000 | 80 | 0.080 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 73 | 0.080 |
Why?
| | Airway Obstruction | 1 | 1991 | 162 | 0.080 |
Why?
| | Analysis of Variance | 6 | 2014 | 1316 | 0.080 |
Why?
| | Endothelin Receptor Antagonists | 3 | 1998 | 62 | 0.080 |
Why?
| | Endothelins | 3 | 2000 | 65 | 0.080 |
Why?
| | Vitamin D | 1 | 2012 | 397 | 0.080 |
Why?
| | Prostaglandins | 2 | 2001 | 97 | 0.070 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2011 | 249 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2199 | 0.070 |
Why?
| | Anesthetics, Combined | 1 | 2008 | 9 | 0.070 |
Why?
| | Regional Blood Flow | 4 | 1998 | 474 | 0.070 |
Why?
| | Patient Readmission | 1 | 2013 | 697 | 0.070 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 167 | 0.070 |
Why?
| | Scotland | 2 | 2018 | 18 | 0.070 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 4 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1719 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 322 | 0.070 |
Why?
| | Receptors, Endothelin | 3 | 2000 | 51 | 0.070 |
Why?
| | Postoperative Period | 3 | 2016 | 342 | 0.070 |
Why?
| | Acute Disease | 2 | 2005 | 1007 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 565 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.070 |
Why?
| | Sex Distribution | 1 | 2008 | 375 | 0.070 |
Why?
| | Neoplasms | 2 | 2019 | 2671 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2526 | 0.070 |
Why?
| | Microspheres | 3 | 1991 | 137 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 108 | 0.060 |
Why?
| | Leukomalacia, Periventricular | 1 | 2006 | 8 | 0.060 |
Why?
| | Purines | 3 | 2013 | 176 | 0.060 |
Why?
| | Piperidines | 1 | 2008 | 206 | 0.060 |
Why?
| | Swine | 2 | 2003 | 775 | 0.060 |
Why?
| | Endothelin-1 | 5 | 2000 | 182 | 0.060 |
Why?
| | Intracranial Hemorrhages | 1 | 2006 | 85 | 0.060 |
Why?
| | Methyl Ethers | 1 | 2005 | 13 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 2 | 1996 | 57 | 0.060 |
Why?
| | Enzyme Inhibitors | 7 | 2005 | 840 | 0.060 |
Why?
| | Lung Compliance | 1 | 2005 | 49 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 1998 | 564 | 0.060 |
Why?
| | Airway Resistance | 1 | 2005 | 41 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2010 | 1079 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 43 | 0.060 |
Why?
| | Electroencephalography | 1 | 2008 | 423 | 0.060 |
Why?
| | Signal Transduction | 3 | 2005 | 5079 | 0.060 |
Why?
| | Anesthetics, Inhalation | 1 | 2005 | 35 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 278 | 0.060 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 243 | 0.060 |
Why?
| | Electric Impedance | 1 | 2005 | 107 | 0.060 |
Why?
| | Prenatal Care | 1 | 2007 | 294 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2006 | 2844 | 0.060 |
Why?
| | Aging | 2 | 1992 | 1864 | 0.060 |
Why?
| | Amides | 1 | 2005 | 93 | 0.060 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2022 | 69 | 0.060 |
Why?
| | Drug Administration Schedule | 4 | 2011 | 786 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1313 | 0.050 |
Why?
| | Rats | 7 | 2005 | 5647 | 0.050 |
Why?
| | Carbon Dioxide | 4 | 1999 | 267 | 0.050 |
Why?
| | Home Nursing | 1 | 2003 | 25 | 0.050 |
Why?
| | Carcinoma | 2 | 2016 | 240 | 0.050 |
Why?
| | Cost-Benefit Analysis | 3 | 2011 | 591 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 1 | 2003 | 93 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2005 | 234 | 0.050 |
Why?
| | Esophagus | 1 | 2005 | 255 | 0.050 |
Why?
| | Birth Weight | 1 | 2006 | 516 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 64 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2024 | 290 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 131 | 0.050 |
Why?
| | Embryonic and Fetal Development | 3 | 2000 | 97 | 0.050 |
Why?
| | Intermittent Positive-Pressure Ventilation | 2 | 1993 | 11 | 0.050 |
Why?
| | Surgical Flaps | 1 | 2023 | 130 | 0.050 |
Why?
| | Forced Expiratory Volume | 2 | 2016 | 531 | 0.050 |
Why?
| | Age Factors | 3 | 2016 | 3295 | 0.050 |
Why?
| | Stomach | 1 | 2002 | 110 | 0.050 |
Why?
| | Mouth Mucosa | 1 | 2022 | 92 | 0.050 |
Why?
| | Analgesics | 1 | 2024 | 206 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2022 | 183 | 0.050 |
Why?
| | Mosaicism | 1 | 2022 | 73 | 0.050 |
Why?
| | Evaluation Studies as Topic | 2 | 1992 | 180 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 191 | 0.050 |
Why?
| | Thyroid Neoplasms | 2 | 2016 | 343 | 0.050 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 45 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5472 | 0.050 |
Why?
| | Phenotype | 2 | 2023 | 3196 | 0.040 |
Why?
| | Uterus | 1 | 2002 | 215 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 382 | 0.040 |
Why?
| | Milrinone | 1 | 2021 | 29 | 0.040 |
Why?
| | Muscle, Smooth | 2 | 2000 | 155 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2001 | 61 | 0.040 |
Why?
| | Ligation | 5 | 2002 | 92 | 0.040 |
Why?
| | Calibration | 1 | 2001 | 146 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 27 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 5778 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 827 | 0.040 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 4 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2837 | 0.040 |
Why?
| | Patient Transfer | 1 | 2002 | 176 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 117 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 37 | 0.040 |
Why?
| | Blotting, Northern | 4 | 2000 | 201 | 0.040 |
Why?
| | Adolescent | 8 | 2005 | 21513 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 207 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 1999 | 245 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 2002 | 321 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 436 | 0.040 |
Why?
| | Digestive System Physiological Phenomena | 1 | 1998 | 4 | 0.040 |
Why?
| | Drug Synergism | 2 | 1998 | 382 | 0.040 |
Why?
| | Leukocyte Count | 2 | 1997 | 329 | 0.040 |
Why?
| | Asphyxia Neonatorum | 1 | 1998 | 17 | 0.040 |
Why?
| | Acidosis | 2 | 1992 | 101 | 0.040 |
Why?
| | Blood Vessels | 1 | 2000 | 187 | 0.040 |
Why?
| | Body Weight | 2 | 2005 | 985 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 1998 | 50 | 0.040 |
Why?
| | Immunohistochemistry | 4 | 2005 | 1738 | 0.030 |
Why?
| | Occipital Bone | 1 | 1997 | 18 | 0.030 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 65 | 0.030 |
Why?
| | Cephalometry | 1 | 1997 | 33 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2757 | 0.030 |
Why?
| | Frontal Bone | 1 | 1997 | 21 | 0.030 |
Why?
| | Potassium Channels | 1 | 1998 | 151 | 0.030 |
Why?
| | Growth | 1 | 1997 | 60 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2002 | 683 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 126 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2016 | 26 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2016 | 38 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 1998 | 2900 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 157 | 0.030 |
Why?
| | Expectorants | 1 | 2016 | 24 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 184 | 0.030 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2016 | 18 | 0.030 |
Why?
| | Nausea | 1 | 1997 | 111 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 285 | 0.030 |
Why?
| | Endothelin-3 | 1 | 1996 | 3 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 199 | 0.030 |
Why?
| | Vascular Patency | 1 | 2016 | 106 | 0.030 |
Why?
| | Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 1 | 0.030 |
Why?
| | Ireland | 1 | 2016 | 30 | 0.030 |
Why?
| | Rats, Inbred Strains | 3 | 1992 | 362 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 696 | 0.030 |
Why?
| | Arginine | 2 | 1994 | 271 | 0.030 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 68 | 0.030 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 36 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 271 | 0.030 |
Why?
| | Vomiting | 1 | 1997 | 130 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1996 | 39 | 0.030 |
Why?
| | Kidney | 3 | 1991 | 1468 | 0.030 |
Why?
| | Gastrostomy | 1 | 1997 | 117 | 0.030 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1998 | 179 | 0.030 |
Why?
| | Lung Injury | 2 | 2011 | 219 | 0.030 |
Why?
| | Luciferases | 1 | 1996 | 150 | 0.030 |
Why?
| | Stroke Volume | 1 | 2019 | 612 | 0.030 |
Why?
| | Blotting, Western | 3 | 2005 | 1226 | 0.030 |
Why?
| | Steroids | 1 | 2016 | 167 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1483 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2015 | 77 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 1997 | 202 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1996 | 269 | 0.030 |
Why?
| | Tyrosine | 1 | 1996 | 222 | 0.030 |
Why?
| | Indiana | 1 | 2015 | 34 | 0.030 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2015 | 59 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 3 | 2001 | 173 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 605 | 0.030 |
Why?
| | Peptides, Cyclic | 4 | 1998 | 259 | 0.030 |
Why?
| | Biological Transport | 3 | 1991 | 418 | 0.030 |
Why?
| | Aorta | 4 | 1998 | 417 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 196 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 1997 | 309 | 0.030 |
Why?
| | Endothelium | 1 | 1995 | 123 | 0.030 |
Why?
| | Base Sequence | 2 | 1996 | 2181 | 0.030 |
Why?
| | Organ Dysfunction Scores | 1 | 2014 | 48 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 396 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 159 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2015 | 141 | 0.030 |
Why?
| | Costs and Cost Analysis | 2 | 2009 | 213 | 0.030 |
Why?
| | Vasomotor System | 3 | 2002 | 47 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 658 | 0.030 |
Why?
| | Life Support Care | 1 | 2014 | 33 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 1992 | 413 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1996 | 378 | 0.030 |
Why?
| | Stress, Mechanical | 3 | 2001 | 485 | 0.030 |
Why?
| | Schools, Medical | 1 | 2015 | 147 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 314 | 0.030 |
Why?
| | Drug Evaluation | 1 | 1993 | 84 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2016 | 287 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 1992 | 1092 | 0.030 |
Why?
| | Reference Values | 3 | 2002 | 816 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 665 | 0.030 |
Why?
| | Young Adult | 1 | 2009 | 13209 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 1997 | 494 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 332 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2734 | 0.020 |
Why?
| | Lactic Acid | 1 | 2014 | 305 | 0.020 |
Why?
| | DNA | 2 | 1998 | 1459 | 0.020 |
Why?
| | United States | 3 | 2012 | 14841 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 63 | 0.020 |
Why?
| | Hypertension | 1 | 2002 | 1295 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 554 | 0.020 |
Why?
| | Ammonium Chloride | 1 | 1992 | 5 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2015 | 313 | 0.020 |
Why?
| | Child Development | 1 | 1997 | 475 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 900 | 0.020 |
Why?
| | Brain | 2 | 1997 | 2668 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1992 | 117 | 0.020 |
Why?
| | Streptococcus agalactiae | 1 | 1993 | 93 | 0.020 |
Why?
| | Nephrons | 1 | 1992 | 18 | 0.020 |
Why?
| | Quality of Life | 2 | 2017 | 2892 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1943 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2011 | 38 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 1995 | 365 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 208 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 2295 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 77 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1070 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1993 | 151 | 0.020 |
Why?
| | Carboxyhemoglobin | 1 | 1991 | 7 | 0.020 |
Why?
| | Radioisotopes | 1 | 1991 | 31 | 0.020 |
Why?
| | Phosphorylation | 1 | 1996 | 1759 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 218 | 0.020 |
Why?
| | Patient Discharge | 1 | 2017 | 897 | 0.020 |
Why?
| | Fetal Diseases | 2 | 2003 | 173 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1250 | 0.020 |
Why?
| | Body Constitution | 1 | 1991 | 55 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 145 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 759 | 0.020 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1993 | 233 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 198 | 0.020 |
Why?
| | Sex Factors | 1 | 2016 | 2071 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2007 | 2833 | 0.020 |
Why?
| | Echovirus Infections | 1 | 1990 | 1 | 0.020 |
Why?
| | Enterovirus B, Human | 1 | 1990 | 26 | 0.020 |
Why?
| | Preoperative Period | 1 | 2010 | 129 | 0.020 |
Why?
| | Meningoencephalitis | 1 | 1990 | 25 | 0.020 |
Why?
| | Medical Audit | 1 | 2010 | 78 | 0.020 |
Why?
| | Burns | 2 | 1991 | 325 | 0.020 |
Why?
| | Guanidines | 2 | 2001 | 39 | 0.020 |
Why?
| | Isoenzymes | 2 | 2001 | 304 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2009 | 110 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2001 | 79 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 117 | 0.020 |
Why?
| | Tetraethylammonium | 2 | 1999 | 16 | 0.020 |
Why?
| | 4-Aminopyridine | 2 | 1999 | 24 | 0.020 |
Why?
| | Pressure | 2 | 2002 | 225 | 0.020 |
Why?
| | Heart Diseases | 1 | 1992 | 346 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 1991 | 391 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 47 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 40 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1996 | 4193 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 2007 | 8 | 0.020 |
Why?
| | Organ Size | 2 | 2005 | 477 | 0.020 |
Why?
| | Receptor, Endothelin B | 2 | 2000 | 51 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1024 | 0.020 |
Why?
| | Heart Rate, Fetal | 2 | 1999 | 21 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 22 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1990 | 652 | 0.020 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 49 | 0.020 |
Why?
| | Developmental Disabilities | 1 | 2009 | 263 | 0.020 |
Why?
| | Protein Precursors | 2 | 2000 | 134 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 815 | 0.020 |
Why?
| | RNA, Viral | 1 | 1990 | 656 | 0.020 |
Why?
| | Proteins | 1 | 1992 | 1009 | 0.020 |
Why?
| | Comorbidity | 1 | 2010 | 1622 | 0.010 |
Why?
| | Thoracic Diseases | 1 | 2005 | 14 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2005 | 33 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1987 | 195 | 0.010 |
Why?
| | Phosphates | 1 | 1986 | 182 | 0.010 |
Why?
| | Oscillometry | 1 | 2005 | 42 | 0.010 |
Why?
| | Manometry | 1 | 2005 | 95 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 86 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 133 | 0.010 |
Why?
| | Muscular Diseases | 1 | 2005 | 114 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4565 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 343 | 0.010 |
Why?
| | Pulse Therapy, Drug | 1 | 2003 | 7 | 0.010 |
Why?
| | Administration, Intranasal | 1 | 2003 | 90 | 0.010 |
Why?
| | Time | 1 | 2003 | 83 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1139 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 506 | 0.010 |
Why?
| | Pharyngectomy | 1 | 2002 | 3 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 976 | 0.010 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 2002 | 5 | 0.010 |
Why?
| | Speech, Alaryngeal | 1 | 2002 | 3 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 29 | 0.010 |
Why?
| | Pyrroles | 1 | 2004 | 213 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 79 | 0.010 |
Why?
| | Laryngectomy | 1 | 2002 | 19 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 44 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1987 | 771 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 1118 | 0.010 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2002 | 77 | 0.010 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2002 | 57 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 29 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 10 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 21 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 27 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 629 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 148 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 431 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 59 | 0.010 |
Why?
| | Glucocorticoids | 1 | 1986 | 594 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 68 | 0.010 |
Why?
| | Lymph Node Excision | 1 | 2002 | 171 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 14 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 41 | 0.010 |
Why?
| | Esophagectomy | 1 | 2002 | 131 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 79 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 159 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 167 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 155 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 305 | 0.010 |
Why?
| | Indoles | 1 | 2004 | 412 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 178 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 664 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 410 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1199 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 65 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1999 | 46 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2486 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 4 | 0.010 |
Why?
| | Atrial Function, Right | 1 | 1998 | 12 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 638 | 0.010 |
Why?
| | Delayed Rectifier Potassium Channels | 1 | 1998 | 9 | 0.010 |
Why?
| | Shab Potassium Channels | 1 | 1998 | 18 | 0.010 |
Why?
| | Digestive System | 1 | 1998 | 27 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1998 | 86 | 0.010 |
Why?
| | Xenopus | 1 | 1998 | 87 | 0.010 |
Why?
| | Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
| | Thiazines | 1 | 1998 | 10 | 0.010 |
Why?
| | Masks | 1 | 1998 | 63 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1998 | 272 | 0.010 |
Why?
| | Long-Term Care | 1 | 1998 | 107 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1502 | 0.010 |
Why?
| | Catheterization | 1 | 1998 | 179 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 860 | 0.010 |
Why?
| | Medical Records | 1 | 1998 | 177 | 0.010 |
Why?
| | Oocytes | 1 | 1998 | 181 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 534 | 0.010 |
Why?
| | Methylene Blue | 1 | 1996 | 24 | 0.010 |
Why?
| | Dogs | 1 | 1998 | 413 | 0.010 |
Why?
| | Indomethacin | 1 | 1996 | 81 | 0.010 |
Why?
| | Microvilli | 2 | 1987 | 78 | 0.010 |
Why?
| | Adenosine | 1 | 1998 | 225 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1996 | 150 | 0.010 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1995 | 8 | 0.010 |
Why?
| | Purinones | 1 | 1995 | 4 | 0.010 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1995 | 8 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 175 | 0.010 |
Why?
| | Receptors, Purinergic P1 | 1 | 1995 | 26 | 0.010 |
Why?
| | Adenocarcinoma, Follicular | 1 | 1995 | 36 | 0.010 |
Why?
| | Sodium | 2 | 1987 | 217 | 0.010 |
Why?
| | Theophylline | 1 | 1995 | 67 | 0.010 |
Why?
| | Arterioles | 1 | 1995 | 52 | 0.010 |
Why?
| | Carcinoma, Papillary | 1 | 1995 | 81 | 0.010 |
Why?
| | Home Care Services | 1 | 1998 | 257 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 81 | 0.010 |
Why?
| | Renal Circulation | 1 | 1995 | 58 | 0.010 |
Why?
| | Phenylephrine | 1 | 1995 | 75 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1995 | 78 | 0.010 |
Why?
| | Viper Venoms | 1 | 1994 | 9 | 0.010 |
Why?
| | Muscle Tonus | 1 | 1994 | 21 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2139 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 510 | 0.010 |
Why?
| | Forecasting | 1 | 1995 | 389 | 0.010 |
Why?
| | Cause of Death | 1 | 1995 | 434 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 213 | 0.010 |
Why?
| | Intestines | 1 | 1995 | 357 | 0.010 |
Why?
| | Chemotaxis | 1 | 1991 | 131 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 1995 | 528 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1990 | 26 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1991 | 201 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1990 | 34 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 190 | 0.010 |
Why?
| | Gene Amplification | 1 | 1990 | 104 | 0.010 |
Why?
| | Cell Count | 1 | 1990 | 324 | 0.000 |
Why?
| | Myocardial Contraction | 1 | 1990 | 341 | 0.000 |
Why?
| | Adenocarcinoma | 1 | 1995 | 940 | 0.000 |
Why?
| | Eosinophils | 1 | 1990 | 332 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1987 | 26 | 0.000 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 1987 | 24 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1990 | 1062 | 0.000 |
Why?
| | Monocytes | 1 | 1990 | 563 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 560 | 0.000 |
Why?
| | Skin | 1 | 1990 | 752 | 0.000 |
Why?
| | Glomerular Filtration Rate | 1 | 1987 | 746 | 0.000 |
Why?
| | Macrophages | 1 | 1990 | 1547 | 0.000 |
Why?
|
|
Kinsella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|